tetano
Editor, Senior Moderator
Vaccine. 2013 Nov 18. pii: S0264-410X(13)01553-3. doi: 10.1016/j.vaccine.2013.11.036. [Epub ahead of print]
One-shot vaccination with an insect cell-derived low-dose influenza A H7 virus-like particle preparation protects mice against H7N9 challenge.
Klausberger M, Wilde M, Palmberger D, Hai R, Albrecht RA, Margine I, Hirsh A, Garc?a-Sastre A, Grabherr R, Krammer F.
Source
Vienna Institute of BioTechnology, University of Natural Resources and Life Sciences, Vienna, Austria; Graduate School of Biological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Abstract
Human infections with a novel influenza A H7N9 subtype influenza virus were reported in China recently. The virus caused severe disease with high mortality rates and it raised concerns over its pandemic potential. Here, we assessed in the mouse model protective efficacy of single immunisations with low vaccine doses of insect cell-derived H7 virus-like particles, consisting of hemagglutinin and matrix protein. Vaccinated mice were fully protected and survived a stringent lethal challenge (100mLD50) with H7N9, even after a single, unadjuvanted, low vaccine dose (0.03μg). Serum analysis revealed broad reactivity and hemagglutination inhibition activity across a panel of divergent H7 strains. Moreover, we detected significant levels of cross-reactivity to related group 2 hemagglutinins. These data demonstrate that virus-like particle vaccines have the potential to induce broadly protective immunity against the novel H7N9 virus and a variety of other H7 strains.
Copyright ? 2013. Published by Elsevier Ltd.
KEYWORDS:
Baculovirus, Cross-reactivity, H7N9, Influenza, Pandemic, Virus-like particle
PMID:
24262313
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/24262313
One-shot vaccination with an insect cell-derived low-dose influenza A H7 virus-like particle preparation protects mice against H7N9 challenge.
Klausberger M, Wilde M, Palmberger D, Hai R, Albrecht RA, Margine I, Hirsh A, Garc?a-Sastre A, Grabherr R, Krammer F.
Source
Vienna Institute of BioTechnology, University of Natural Resources and Life Sciences, Vienna, Austria; Graduate School of Biological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Abstract
Human infections with a novel influenza A H7N9 subtype influenza virus were reported in China recently. The virus caused severe disease with high mortality rates and it raised concerns over its pandemic potential. Here, we assessed in the mouse model protective efficacy of single immunisations with low vaccine doses of insect cell-derived H7 virus-like particles, consisting of hemagglutinin and matrix protein. Vaccinated mice were fully protected and survived a stringent lethal challenge (100mLD50) with H7N9, even after a single, unadjuvanted, low vaccine dose (0.03μg). Serum analysis revealed broad reactivity and hemagglutination inhibition activity across a panel of divergent H7 strains. Moreover, we detected significant levels of cross-reactivity to related group 2 hemagglutinins. These data demonstrate that virus-like particle vaccines have the potential to induce broadly protective immunity against the novel H7N9 virus and a variety of other H7 strains.
Copyright ? 2013. Published by Elsevier Ltd.
KEYWORDS:
Baculovirus, Cross-reactivity, H7N9, Influenza, Pandemic, Virus-like particle
PMID:
24262313
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/24262313